Mave Health raises $2.1 million seed round

Neurotechnology startup Mave Health has raised $2.1 million (INR 18 crore) in a seed funding round led by Blume Ventures. The round also saw participation from Inuka Capital, Stanford Angels, Founders of Groww, Raymond Russell, Aureolis Ventures and Juhi Bhatnagar (Forj Capital), with existing investors, including All In Capital, doubling down on their investment. The funding follows the company’s $750K pre-seed round raised in November 2023.

Founded in 2023 by Dhawal Jain, Jai Sharma, and Aman Kumar, Mave Health is building a wearable headset that supports everyday mental health and cognitive performance in just 20 minutes a day. Its underlying technology, transcranial direct current stimulation (tDCS), has been studied for over 25 years, with more than 10,000 published papers globally. tDCS has a safety profile and is well-suited for at-home use. Mave packages this into a lightweight, consumer-friendly device.

Mave debuted with over 500 beta customers ahead of its public release last month. Based on self-reported data collected after four weeks of use, 80% reported productivity gains exceeding 60%, 75% reported stress reductions above 50% and users reported an average mood improvement of 77%.


Dhawal Jain, Co-founder and CEO of Mave Health said in a statement “The brain is the most complex system we rely on every day, and modern life is constantly overloading it. We expect it to perform at peak levels without giving it the support it needs.” “Instead of chasing short-term boosts that come with long-term costs, we believe in strengthening the underlying systems that drive focus, mood, and stress regulation. Our goal is to make brain health tools as accessible and routine as fitness trackers.”

The newly raised capital will be used to launch Mave’s wearable headset in the United States and India, and to expand manufacturing capabilities.

Arpit Agarwal, Investment Partner at Blume Ventures said in a statement “Neurotechnology has the potential to enhance human experience. New-age microelectronic devices like Mave are making it accessible to consumers by moving beyond the clinic, in a way that merges seamlessly with our lifestyle. This could shift the way individuals manage their mood, stress and overall well-being. We are excited to partner with the team which is passionate about building a category-defining consumer device company from India for the global market."

The Mave headset delivers low-intensity electrical stimulation designed to strengthen the prefrontal cortex; the brain region associated with attention, emotional regulation, and stress response. Users wear the lightweight (~100g) device for 20 minutes a day while going about their routine. The headset lasts up to a month on a single charge with regular use. The companion app allows users to log sessions, personalize protocols, and track progress without collecting any brain data. Most users report noticeable improvements within 15 to 20 days, with benefits compounding over time.